in

Jakubowitz Law Reminds Molecular Partners Shareholders of a Lead Plaintiff Deadline of September 12, 2022


NEW YORK, Aug. 12, 2022 /PRNewswire/ — Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Molecular Partners AG (NASDAQ: MOLN).

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/molecular-partners-ag-loss-submission-form/?id=30779&from=4

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company’s initial public offering conducted on or about June 16, 2021; and/or (b) Molecular Partners securities between June 16, 2021, and April 26, 2022.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until September 12, 2022 to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

According to a filed complaint, Molecular Partners AG issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization (“EUA”); (iii) waning global rates of COVID-19 significantly reduced the Company’s chances of securing EUA for ensovibep; (iv) another of the Company’s product candidates, MP0310, was less attractive to Molecular Partners’ collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company’s initial public offer and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE Jakubowitz Law



Original post Source link

We do NOT claim any copyrights on the text or Image, the rights belong to their respective owner.

DISCLAIMER:
Below Part 107 of the Copyright Act 1976, allowance is made for “honest use” for functions reminiscent of criticism, remark, information reporting, educating, scholarship, and analysis. Truthful use is a use permitted by copyright statute which may in any other case be infringing.”

What do you think?

64 Points
Upvote Downvote

Written by Newsplaneta

Leave a Reply

Your email address will not be published.

GIPHY App Key not set. Please check settings

Each Music Ranked On Megan Thee Stallion’s ‘Traumazine’ Album – Billboard

ASIC chair troubled by sheer quantity of ‘risk-taking’ crypto buyers